CIPO trademark

TEVA PACKAGE DESIGN J

RegisteredCIPOFigurative markClass 5

"TEVA PACKAGE DESIGN J" is a figurative mark owned by Teva Pharmaceutical Industries Ltd., filed at the CIPO on August 14, 2019. It is registered and covers class 5 (Pharmaceuticals).

View Teva Pharmaceutical Industries Ltd. portfolio Get this data via the API

Data current as of June 14, 2025Official CIPO record

As filed with the CIPO

Status: Registered; Since September 9, 2024
Filed: August 14, 2019
Registered: September 9, 2024
Expires: September 9, 2034
Application no.: 1980471
Registration no.: TMA1254464
Office: CIPO; Canadian Intellectual Property Office
Mark type: Figurative mark; 1 class

Ownership

Who owns TEVA PACKAGE DESIGN J

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Teva Pharmaceutical Industries Ltd.

Israel

1,141 trademarks in the portfolioView company

Representative

Osler, Hoskin & Harcourt LLP

Goods and services

What the mark covers

The products and services TEVA PACKAGE DESIGN J is filed for, grouped by Nice class.

05Class 5 · Pharmaceuticals
Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations for human use; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; Pharmaceutical preparations for the treatment of circulatory system diseases and disorders; Pharmaceutical preparations for the treatment of sensory organ disorders; Pharmaceutical preparations for the treatment of urogenital organ disorders; Pharmaceutical preparations for the treatment of peripheral nervous system disorders; Pharmaceutical preparations for the treatment of neurological disorders.

History

What has happened so far

Steps recorded by the CIPO, newest first.

September 9, 2024Registered
September 9, 2024Registration Pending
June 19, 2024Advertised; Vol.71 Issue 3634
May 27, 2024Approval Notice Sent; APPROVED BY PROGRAM EX200M1
May 27, 2024Approved; APPROVED BY PROGRAM EX200M1
May 10, 2024Examiner's First Report
May 10, 2024Search Recorded
April 12, 2022Pre-Assessment Letter Sent; Retired Goods or Services
February 28, 2022Voir Preuve au dossier/See evidence on File No. 2121983
February 28, 2022Amendment to Application; Owner Address Change / Voir Preuve au dossier/See evidence on File No. 2121983

3 earlier steps on the official record.

FAQ

About TEVA PACKAGE DESIGN J

Who owns the trademark "TEVA PACKAGE DESIGN J"?

The CIPO trademark "TEVA PACKAGE DESIGN J" (application 1980471) is owned by Teva Pharmaceutical Industries Ltd.

What is the status of "TEVA PACKAGE DESIGN J"?

Its status at the CIPO is: registered.

When was "TEVA PACKAGE DESIGN J" registered?

It was registered on September 9, 2024 and is due to expire on September 9, 2034.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull TEVA PACKAGE DESIGN J and marks like it into your own product with one request.

GET/v1/trademarks/{id}
The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/events
Every step in the office history
GET/v1/proceedings?trademark_id={id}
Oppositions and cancellations against the mark

Get API key View docs

GET /v1/trademarks/{id}

ID=tm_019deb24-316c-7577-9035-06a5ee0bf9be
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"

Response

{
  "id": "tm_019deb24-316c-7577-9035-06a5ee0bf9be",
  "object": "trademark",
  "mark_text": "TEVA PACKAGE DESIGN J",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "CA",
  "application_number": "1980471",
  "filing_date": "2019-08-14",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "Teva Pharmaceutical Industries Ltd.",
      "entity_id": "ent_019ebbc5-6f32-7092-a649-5aaa7b712e21"
    }
  ]
}